0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > CA125

CA125

Brief Information

Name:Mucin-16
Target Synonym:Mucin-16 Short Isoform,Mucin-16 Long Isoform,Ovarian carcinoma antigen CA125,Ovarian cancer-related tumor marker CA125,MUC16,MUC-16,CA-125,Mucin 16, Cell Surface Associated,CA125,CA125 Ovarian Cancer Antigen,Mucin-16,CA-125 Antigen,FLJ14303
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CA5-M52H6-SPR
 CA125 SPR

Biotinylated Mouse Mesothelin, His,Avitag (Cat. No. MSN-M82E7) immobilized on CM5 Chip can bind Mouse CA125 Protein, His Tag (Cat. No. CA5-M52H6) with an affinity constant of 16.4 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

CA5-H52H6-SPR
 CA125 SPR

Human Mesothelin (296-580), His Tag, premium grade (Cat. No. MSN-H522a) immobilized on CM5 Chip can bind Human CA125 (13810-14451), His Tag (Cat. No. CA5-H52H6) with an affinity constant of 1.82 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

CA125,CA-125,CA125MUC-16,FLJ14303,MUC16,mucin 16,mucin-16

Background

The CA125, also known as the MUC16, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy. The CA 125 molecule is almost certainly a glycoprotein with a predominance of O-linkages. It is heterogeneous with regard to both size and charge, most likely due to continuous deglycosylation of side chains during its life-span in bodily fluids. It exists as a very large complex (perhaps as much as 4 million daltons) under natural conditions.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Oregovomab B43.13 Phase 3 Clinical Paladin Pharma Ovarian Neoplasms; Carcinoma; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma Details
LBL-033 LBL-033 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Neoplasms Details
REGN-5668 REGN-5668 Phase 2 Clinical Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms Details
Ubamatamab REGN-4018 Phase 2 Clinical Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms Details
PRGN-3005 PRGN-3005 Phase 1 Clinical Precigen Inc Ovarian Neoplasms; Esophageal Neoplasms; Sarcoma; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms Details
JCAR-020 JCAR-020 Phase 1 Clinical Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc Solid tumours; Neoplasms Details
huAR9.6-IRDye800 University Of Nebraska Medical Center Details
Oregovomab B43.13 Phase 3 Clinical Paladin Pharma Ovarian Neoplasms; Carcinoma; Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Adenocarcinoma Details
LBL-033 LBL-033 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Neoplasms Details
REGN-5668 REGN-5668 Phase 2 Clinical Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms Details
Ubamatamab REGN-4018 Phase 2 Clinical Ovarian Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms Details
PRGN-3005 PRGN-3005 Phase 1 Clinical Precigen Inc Ovarian Neoplasms; Esophageal Neoplasms; Sarcoma; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms Details
JCAR-020 JCAR-020 Phase 1 Clinical Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc Solid tumours; Neoplasms Details
huAR9.6-IRDye800 University Of Nebraska Medical Center Details

This web search service is supported by Google Inc.

totop

Laisser un message